Liver disease is a complex multi-stage medical phenomenon that can develop insidiously over decades. Early on, a patient may present with deranged liver enzymes without any signs. In the latter case one could develop liver fibrosis, and if even more advanced, cirrhosis. You may think of cirrhosis as just “liver weakness,” but this perception, while common, does not convey the chronic fibrotic scarring and architectural distortion of liver tissue that occurs with this disease process, in addition to the inflammatory response with impaired regeneration and loss of functional hepatic parenchyma.
UC-MSC Thailand is one of the most searched topics amongst patients looking for liver supportive regenerative medicine, and part of that reason is here. UC-MSCs, or umbilical cord-derived mesenchymal stem/stromal cells, are being investigated due to their potential immunomodulatory, anti-inflammatory and anti-fibrotic functional tissue supporting signalling properties. A caveat for liver stem cell therapy. Do not label it as a cure for cirrhosis or replacement of hepatology care.
Current guidelines in hepatology still advocate for the importance of appropriate diagnosis, disease staging, cause-specific treatment, monitoring for complications and long-term management of liver disease. AASLD defines its practice guidance as an evidence basis for clinical treatment and management decisions.
Medical Staging of Liver Fibrosis and Cirrhosis: Why it Matters?
Before talking about UC-MSC Thailand and liver disease, one has to know how to stage the liver. Liver disease could be due to viral hepatitis, alcohol-related liver disease, metabolic dysfunctionrelated steatotic liver disease (MASLD), autoimmune liver disease, drug-induced liver injury, biliary tract illness or genetic disorder.
Liver function tests, bilirubin, albumin, platelet count, PT/INR (if indicated), viral hepatitis serology (HBsAg + anti-HBc) + ultrasound (if suspected HCC), FibroScan or MRI surgically ± CT +/- endoscopy if variceal bleeding is suggested ≥ 20% probability: Child-Pugh or MELD (for decompensated liver cirrhosis).
Why Staging Matters
A patient with early fibrosis is totally different from a patient with decompensated cirrhosis, ascites, variceal bleeding, jaundice hepatic encephalopathy or liver cancer risk. Then, on the other hand, any of the stem cell treatments programs for liver that are generated inside UC-MSC Thailand should be The best start by the more thorough liver staging instead of by offering to every phenotype a general offer without specific approaches to their therapeutic management.
AASLD guidance for fatty liver disease, which is also up-to-date through October 2023, highlights that when cirrhosis is suspected based on non-invasive tests, clinical data or imaging, cirrhosis-based management may be performed without the need for a liver biopsy in selected patients.
Definition of Liver Stem Cell Therapy
Liver stem cell therapy includes different regenerative medicine approaches focusing on potential therapies for liver injury, liver fibrosis, cirrhosis, acute-on-chronic liver failure and end-stage liver disease. Mesenchymal stem/stromal cells have become a focus of research in this area due to their ability to secrete bioactive molecules capable of influencing immune responses, inflammatory pathways, fibrotic signaling, oxidative stress and tissue repair processes.
Within this context, a scientific rationale is helping UC-MSCs not “becoming new liver tissue”. But much of it has to do with paracrine signaling, which suggests that the cells might secrete growth factors or cytokines or even extracellular vesicles and other biologically active molecules that send messages to neighboring tissues.
UC-MSC-associated mechanisms are being explored for putative actions on:
inflammatory signaling
immune regulation
hepatic stellate cell activity
fibrosis-related pathways
oxidative stress balance
angiogenesis and microcirculation
hepatocyte survival signaling
tissue repair microenvironment
Reviews on stem cell approaches for liver fibrosis and cirrhosis reported increasing interest besides an emerging voice from early-phase studies, but the field is still in need for stronger clinical evidence and standardization before generalizable conclusions can be drawn.
The Findings of the Studies on UC-MSCs and Liver Cirrhosis
In the field of mesenchymal stem/stromal cells in liver disease, three areas have been studied: liver cirrhosis, acute-on-chronic liver failure and end-stage liver disease. A review published in 2025 provided an overview on the status of clinical and preclinical data of MSC application for end-stage liver disease, as well as possible mechanisms including modulation of innate and adaptive immunity along with anti-fibrotic, anti-inflammatory signaling pathways and support of liver regeneration.
MSCs derived from human umbilical cord have also been explored in clinical trials for the treatment of decompensated liver cirrhosis, including HBV-associated cirrhosis. These studies indicate the increased interest of science in this problem, but should not be mistaken for evidence that UC-MSCs are a gold standard treatment for every patient with liver pathology.